SynthesisBMC infectious diseases2010
The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology.
Synthesis in BMC infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review.PharmacoEconomics · 2013Pooled it
- Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.Human vaccines & immunotherapeutics · 2015Trial
- Host-Driven Genetic Diversity ofTransboundary and emerging diseases · 2026Article
- Genetic and Antigenic Diversity ofPathogens (Basel, Switzerland) · 2025Article
- Molecular characterization of invasiveFrontiers in cellular and infection microbiology · 2023Article
- The spread of chloramphenicol-resistant Neisseria meningitidis in Southeast Asia.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- A homopolymeric adenosine tract in the promoter region of nspA influences factor H-mediated serum resistance in Neisseria meningitidis.Scientific reports · 2019Article
- B Part of It study: a longitudinal study to assess carriage of Neisseria meningitidis in first year university students in South Australia.Human vaccines & immunotherapeutics · 2019Article
- A Novel Target Pathogen Identification and Tracking System Using Capillary Electrophoresis-Random Amplified Polymorphic DNA.Scientific reports · 2018Article
- Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines.Human vaccines & immunotherapeutics · 2018Article
- Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States.Therapeutic advances in vaccines · 2017Review
- Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.Human vaccines & immunotherapeutics · 2016Article
- Serogroup and Clonal Characterization of Czech Invasive Neisseria meningitidis Strains Isolated from 1971 to 2015.PloS one · 2016Article
- Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives.Journal of preventive medicine and hygiene · 2015Review
- Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.PloS one · 2015Article
- The association of meningococcal disease with influenza in the United States, 1989-2009.PloS one · 2014Article
- Letter to the editor.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2014Article
- A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.Drugs · 2014Review
- Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: a survey.Human vaccines & immunotherapeutics · 2014Article
- Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy.Human vaccines & immunotherapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundInvasive meningococcal disease (IMD), is a widely distributed, complex human disease affecting all age categories. The causative agent, Neisseria meningitidis, is spread through aerosol respiratory droplets. 13 different serogroups have been identified, each with varying epidemiological features including prevalence, virulence, immunogenicity, geographical and temporal distribution. Although preventative measures are available for several of the serogroups, meningococcal disease caused by serogroup B is of particular interest due to the challenge it presents concerning vaccine development.
methodsA systematic review of peer reviewed studies and reports, the collection of data from national and international health resources, along with the analysis of the Multi Locus Sequence Typing database was carried out aimed at collecting information concerning serogroup B IMD and the epidemiology attached to it.
resultsA continuous output of related and novel STs occurring worldwide in terms of the hypervirulent clonal complexes was observed both in published studies and the MLST database in this case using the eburst software, which highlights the genetically diverse nature of serogroup B strains.
conclusionsWith the recent dominance of serogroup B IMD seen in many countries, along with the presence of antibiotic resistance, vaccine development needs to target areas of the bacterium which tackle this widespread and heterogeneous aspect of meningococcal meningitis disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.